Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CACNB4 | O00305 | 2/20 | 0.45 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.45 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.45 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.45 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.45 |
| ▸ | CACNG7 | P62955 | 2/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.45 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.45 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.45 |
| ▸ | CACNG1 | Q06432 | 2/20 | 0.45 |
| ▸ | CACNB2 | Q08289 | 2/20 | 0.45 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.45 |
| ▸ | CACNA1E | Q15878 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553509 | 1.00 | GPR119 (0.49) | GPR119MEN1KMT2ACACNB4CACNA1A | |
| SCHEMBL553508 | 1.00 | GPR119 (0.49) | GPR119MEN1KMT2ACACNB4CACNA1A | |
| SCHEMBL553728 | 0.86 | MEN1 (0.50) | GPR119MEN1KMT2ACACNB4CACNA1A | |
| SCHEMBL554530 | 0.86 | MEN1 (0.50) | GPR119MEN1KMT2ACACNB4CACNA1A | |
| SCHEMBL31450899 | 0.86 | MEN1 (0.50) | GPR119MEN1KMT2ACACNB4CACNA1A | |
| SCHEMBL553729 | 0.86 | MEN1 (0.50) | GPR119MEN1KMT2ACACNB4CACNA1A | |
| SCHEMBL570865 | 0.84 | MGLL (0.42) | MEN1KMT2A | |
| SCHEMBL554607 | 0.83 | BCL2 (0.46) | GPR119NPSR1 | |
| SCHEMBL554433 | 0.83 | BCL2 (0.46) | GPR119NPSR1 | |
| SCHEMBL554432 | 0.83 | BCL2 (0.46) | GPR119NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017251-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | GPR119 1186/4885MEN1 2368/4885KMT2A 2562/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | GPR119 1186/4885MEN1 2368/4885KMT2A 2562/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | GPR119 1186/4885MEN1 2368/4885KMT2A 2562/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | GPR119 2239/4885MEN1 4724/4885KMT2A 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.